Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any ...

A landmark clinical trial has discovered that omalizumab, marketed as Xolair, provides more effective treatment for multiple food allergies than the current standard approach of oral immunotherapy ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...

OMLYCLO ® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating ...

Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) Meningococcal vaccine For active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in ...

"The most effective health-promoting solution would be to effectively end food insecurity through social policies and an augmented social safety net." HealthDay News — The US Preventive Services ...

Financial services companies may feel relief from the aggressive federal oversight and regulation that defined the past decade. However, regulatory risk has not disappeared—it has shifted.

“We are proud to achieve the approval of the first biosimilar to omalizumab in the U.S., which will help broaden access to this important medicine for patients with allergic and respiratory conditions ...